Human Papillomavirus Vaccination in Saudi Arabia: A Narrative Review of Current Evidence Authors: Abdulrahman M. M. Alqahtani, Mohammed S. S. Alshahrani, Ebtesam Almajed, Rawan A. Bin Salamah, Norah Alqntash, Amina M. Biju, Mohima S. Meem, Fawaz Pullishery Published: 2024 ABSTRACT ABSTRACTHuman papillomavirus (HPV) represents the most common sexually transmitted infection globally, exerting a substantial impact on sexual and reproductive health, with a high oncogenic potential leading to various malignancies. The prevalence of HPV in Saudi Arabia ranges from 9% to 43%, with types 16, 18, and 45 being the most common high-risk strains. Despite the availability of effective vaccines such as Gardasil 9, Gardasil, and Cervarix, proper awareness and vaccination rates remain low in Saudi Arabia. Only 4% of the population has received the HPV vaccine. The Saudi Ministry of Health has integrated HPV vaccines into the national immunization schedule, offering them free of charge and ensuring their availability for adolescent girls and women. However, challenges persist, including cultural and religious beliefs, inadequate healthcare infrastructure, and insufficient public awareness. To effectively increase HPV vaccination coverage, it is crucial to implement comprehensive public education campaigns, actively involve healthcare professionals, and address cultural and religious concerns with sensitivity and respect. International collaboration, such as initiatives by the Gavi alliance and sustained research efforts, is critical to optimizing HPV vaccine efficacy, accessibility, and uptake. Through coordinated efforts, the global burden of HPV-related diseases can be significantly reduced, ultimately leading to improved public health outcomes. INTRODUCTION With more than a million daily cases, sexually transmitted diseases (STDs) pose a significant burden on global sexual and reproductive health.[1] More than 30 different microbes have been identified with the potential to be transmitted via sexual contact or even from mother to child. A review of the global disease burden identified eight prevalent sexually transmitted infections (STIs) amenable to cure. Trichomoniasis exhibited the highest incidence, with an estimated 156 million cases reported worldwide in 2020. Chlamydia followed closely with 129 million cases, while gonorrhea and syphilis presented with 82 million and 7.1 million cases, respectively.[2] In contrast, viral infections such as hepatitis B, herpes simplex virus (HSV), HIV, and human papillomavirus (HPV) are considered incurable. Among these, HPV remains the most common and widespread sexually transmitted infection (STI) globally.[3] Before the age of 45, 80% of sexually active individuals are estimated to contract at least one HPV infection.[4] Males are known to have higher rates of HPV infections compared to females.[5] There are around 200 types of HPV that can transmit sexually, with at least 12 types known to be oncogenic.[6] Among these 12 types, HPV 16 and HPV 18 have been demonstrably implicated in the majority of HPV-related cancers.[7] Most cervical cancer cases are caused by HPVs, 90% of anal, 75% vaginal, 70% throat, 69% vulvar, and 63% of penile cancer cases. Furthermore, data from the World Health Organization (WHO) suggests that HPVs are attributable to approximately 5.0% of annual cancer cases, translating to an estimated 630,000 cases worldwide.[7] Significance of HPV vaccination Vaccination represents the most efficacious strategy for preventing HPV infection. A prime example is Gardasil 9, recommended by the Centers for Disease Control and Prevention (CDC). With high efficacy (90% efficacy), Gardasil 9 offers protection against nine HPV strains, including seven linked to various cancers (types 16, 18, 31, 33, 45, 52, and 58) and two associated with genital warts (types 6 and 11). Vaccination with Gardasil 9 is currently recommended for pre-adolescents (aged 9–12 years) for both males and females.[7] Context of HPV vaccination in Saudi Arabia Prevalence and impact Data generated by hospital-based studies indicate that HPV prevalence in Saudi Arabia ranges from 9% to 43%. Among the most prevalent types, HPV 16 (30%), HPV 18 (8%), and HPV 45 (5%) are recognized as being high-risk types associated with cervical cancer.[8] A recent report published by the International Agency for Research on Cancer (ICO/IARC) found that HPV infection has posed a significant threat to the health of approximately 10.7 million Saudi women and has caused the death of roughly 55 women annually.[89] Moreover, based on a five-year population-based study conducted by Sait et al.,[8] the incidence rate of HPV in Saudi women was reported to be 47 per 100,000 population. Despite the low prevalence and transmission rates of HPV among Saudi women, the primary concern remains the young Saudi population. These demographics warrant further investigation into the associated risk factors and underscore the necessity of enhancing screening programs nationwide. Awareness and knowledge levels Although studies on the assessment of knowledge or awareness related to HPV in the Saudi population are scarce, a cross-sectional observational study was conducted by Almaghlouth in 2022. According to this study, with 645 participants, a significant knowledge gap was identified; only 4% had received their HPV vaccination, and most participants lacked awareness of HPV infection and its corresponding vaccine.[10] HPV vaccination Types of vaccines and their efficacy To date, the U.S. FDA has approved three HPV vaccines. While these vaccines do not provide protection against all HPV strains, they are 100% effective against the high-risk types responsible for 90% of all cervical cancers, as well as vaginal, vulvar, penile, throat, and anal cancers. The three commonly available vaccines are: Gardasil 9, also known as the 9-valent HPV vaccine (9vHPV), provides immunity against nine strains of HPV. These include seven high-risk types (16, 18, 31, 33, 45, 52, 58, and 2) and low-risk genital wart-causing types (6 and 11).Gardasil, also known as the quadrivalent HPV vaccine (4vHPV), protects against four strains of HPV. This includes two carcinogenic types (16 and 18), which are associated with cervical and other cancers, and two types (6 and 11) that cause genital warts.Cervarix, also known as the bivalent HPV vaccine (2vHPV), protects against HPV Types 16 and 18 only. Gardasil 9, also known as the 9-valent HPV vaccine (9vHPV), provides immunity against nine strains of HPV. These include seven high-risk types (16, 18, 31, 33, 45, 52, 58, and 2) and low-risk genital wart-causing types (6 and 11). Gardasil 9, also known as the 9-valent HPV vaccine (9vHPV), provides immunity against nine strains of HPV. These include seven high-risk types (16, 18, 31, 33, 45, 52, 58, and 2) and low-risk genital wart-causing types (6 and 11). Gardasil, also known as the quadrivalent HPV vaccine (4vHPV), protects against four strains of HPV. This includes two carcinogenic types (16 and 18), which are associated with cervical and other cancers, and two types (6 and 11) that cause genital warts. Gardasil, also known as the quadrivalent HPV vaccine (4vHPV), protects against four strains of HPV. This includes two carcinogenic types (16 and 18), which are associated with cervical and other cancers, and two types (6 and 11) that cause genital warts. Cervarix, also known as the bivalent HPV vaccine (2vHPV), protects against HPV Types 16 and 18 only. Cervarix, also known as the bivalent HPV vaccine (2vHPV), protects against HPV Types 16 and 18 only. Saudi Arabian vaccination recommendations In 2010, Saudi Arabia approved Cervarix® and Quadrivalent Gardasil® for females aged 11–26. Both vaccines require three doses to be administered within six months.[11] According to a four-year follow-up study, only two doses of Cervarix were sufficient to provide the level of protection expected from three doses.[12] In Saudi Arabia, the Ministry of Health (MOH) in March 2022 included HPV vaccines and made them freely available to the public under the Saudi Immunization Schedule. Later, in September 2022, vaccination was expanded to include younger age groups. The Saudi Arabia MOH recommends the following vaccination schedule for females of different age groups.[13] Girls aged 9–14 years with one or two doses.Young adolescents aged 15–20 years with one or two doses.Females older than 21 years are recommended to take two doses within six months. Girls aged 9–14 years with one or two doses. Girls aged 9–14 years with one or two doses. Young adolescents aged 15–20 years with one or two doses. Young adolescents aged 15–20 years with one or two doses. Females older than 21 years are recommended to take two doses within six months. Females older than 21 years are recommended to take two doses within six months. Implementation Government policies Based on the WHO recommendations, young females (9–14 years) must be vaccinated for HPV, preferably before they become sexually active. To implement such a recommendation, WHO advised its member states to include the HPV vaccine in their national immunization programs, to which almost all countries complied. A similar gesture regarding implementation of the HPV vaccination program was demonstrated by Saudi Arabia in 2017. Although approval for two of the three FDA-approved HPV vaccines was given in 2010, the implementation kept lagging. However, after the WHO recommendation, the vaccination program was finally included in the national immunization schedule by the Saudi Arabia Ministry of Health. In addition to this inclusion, the Saudi Arabian Ministry of Health made the pap smear test accessible in its public hospitals. It subsidized it to under $50 in private hospitals to facilitate the national HPV screening programs.[13] Vaccine availability and accessibility According to the World Health Organization (WHO), as of March 2022, 60% of its member states, totaling 117 countries, have effectively incorporated HPV vaccination into their respective national immunization schedules. This implementation signifies that approximately one-third of the global population can access HPV vaccines either free of charge or at significantly subsidized costs.[14] Considering the burden of HPV infections, especially in low- and middle-income countries, various bodies formed an alliance called Gavi back in 2000, in order to ensure the global accessibility of vaccines, especially to poor nations. Through Gavi, approximately 1 billion children across 78 lower-income countries have received essential vaccinations, a contribution estimated to have prevented approximately 17.3 million deaths.[15] Implementation challenges Despite these efforts, vaccination drives, particularly in low- and middle-income countries, face challenges due to limited coverage resulting from the absence of national programs and inadequate or insufficient human resources to implement and complete these drives.[14] In addition to economic and administrative barriers, numerous studies across the world report negative attitudes or insufficient knowledge regarding the HPV vaccination.[1113] There have been reports from countries like Saudi Arabia of direct refusal to take the vaccine based on religious beliefs or due to inadequate awareness.[81014] Awareness campaigns Governments and health organizations should distribute pamphlets, posters, and digital content to highlight the benefits of the HPV vaccine and the dangers of HPV infections. A representative and impactful example is the CDC’s campaigns, which feature testimonials from cervical cancer survivors and medical experts explaining the vaccine’s benefits.[16] These campaigns should be available in schools, clinics, and social media to maximize outreach and impact. Healthcare professional involvement As healthcare professionals are in direct contact with patients, their education and advocacy can play a pivotal role in increasing HPV vaccine uptake. This requires well-trained doctors, nurses, and other healthcare providers who understand and can effectively communicate the importance of the HPV vaccine to their patients. Resources like the CDC’s guidelines help standardize this training.[17] Additionally, during patient counselling, healthcare professionals can discuss the benefits of the HPV vaccine with parents and patients, addressing any concerns or misconceptions. This personalized approach is often more effective in convincing hesitant individuals to vaccinate. Then comes community engagement, which includes the participation of healthcare professionals in community health fairs and workshops, providing on-site vaccinations, and information sessions to educate the public directly. Addressing cultural and religious factors Studies prove that cultural and religious beliefs can significantly impact vaccine acceptance. Therefore, addressing these factors is essential for successful HPV vaccination programs. Such goals can be achieved mainly by engaging with community and religious leaders to endorse the HPV vaccine, which can help gain public trust and acceptance. Their support can dispel myths and encourage vaccination within their communities. Furthermore, while doing so, the advocates must ensure their campaigns are tailored to respect cultural norms and values; this includes using appropriate language, respecting gender norms, and ensuring that materials are culturally relevant. In addition, organizing educational workshops that include religious and cultural perspectives on health can help bridge gaps and create a more inclusive approach to vaccination. Future perspectives Strategies for increased coverage Along with supporting and promoting universal vaccination programs such as Gavi, the health ministry and education ministry must work together to ensure pre-teens are protected before they become sexually active. Additionally, the vaccine can be made available for free or at a discounted rate in order to remove financial barriers. Furthermore, legislative measures can be implemented by implementing policies that require HPV vaccination for students before they enter school in order to ensure greater coverage rates. For instance, several states in the US have such requirements for middle school students.[18] Research and development Ongoing research and developmental efforts aim to monitor and improve the HPV vaccination with an understanding of its long-term impacts, including developing HPV vaccines that cover more strains and require fewer doses with enhanced efficacy, minimal cost, and compliance. Furthermore, proper funding and data access must be provided to the researchers to monitor and evaluate the vaccine’s safety and effectiveness, help refine the vaccination strategies, and address any emerging issues. In addition to the above measures, public health studies must be promoted to understand the impact of HPV vaccination on population health, including potential reductions in other HPV-related cancers, which can provide valuable data to support vaccine programs at the international level. International collaboration Eradication of any communicable infection is impossible at the national level. Therefore, global collaboration and cooperation are essential to tackling HPV infections effectively. Collaborating with international organizations, including WHO, Gavi, and UNICEF, will ensure and monitor the local governments in providing the vaccines with the necessary supporting infrastructure required for vaccine delivery and distribution to the masses. Another aspect of international collaboration is knowledge sharing, where countries share their best practices and lessons learned through international forums and collaborations, which leads to improved global vaccination strategies. Finally, through supportive funding initiatives, high-income countries and global health organizations can provide financial and technical assistance to low- and middle-income countries, ensuring equitable access to HPV vaccines. CONCLUSION HPV poses a substantial global sexual and reproductive health burden. Additionally, carcinogenic strains of HPV further add to the worldwide morbidity and mortality, primarily by causing cervical and other associated cancers. The fight against HPV and cervical cancer requires a multi-faceted approach involving public awareness, healthcare professional involvement, and sensitivity to cultural and religious factors. Future strategies focusing on increased coverage, ongoing research, and international collaboration are essential to achieving global HPV vaccination goals and significantly reducing the burden of cervical cancer worldwide. Conflicts of interest There are no conflicts of interest.